

<div style="display: flex; justify-content: space-between;"> <span>RECEIVED</span> <span>Box 5631/\$</span> </div> <div style="display: flex; justify-content: space-between;"> <span>CERTIFICATE OF MAILING</span> <span>SEP 06 2000</span> </div>																	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231																	
Typed or Printed Name	Mathew Otts <span style="float: right;">TECH CENTER 1600/2900</span>																
Signature		Date	August 28, 2000 <span style="float: right;">SEP - 5 2000</span>														
<div style="text-align: center;"> <b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i> </div> <div style="text-align: center; margin-top: 20px;"> </div>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Attorney Docket</td> <td style="width: 50%;">1481.002 <span style="float: right;">TECH CE: 90/290</span></td> </tr> <tr> <td>First Named Inventor</td> <td>Williams, et al.</td> </tr> <tr> <td>Application Number</td> <td>09/297,648</td> </tr> <tr> <td>Filing Date</td> <td>March 10, 2000</td> </tr> <tr> <td>Group Art Unit</td> <td>1631</td> </tr> <tr> <td>Examiner Name</td> <td>J. Brusca</td> </tr> <tr> <td colspan="2" style="padding: 5px;">           Title: "HUMAN GENES AND GENE EXPRESSION PRODUCTS II"         </td> </tr> </table>		Attorney Docket	1481.002 <span style="float: right;">TECH CE: 90/290</span>	First Named Inventor	Williams, et al.	Application Number	09/297,648	Filing Date	March 10, 2000	Group Art Unit	1631	Examiner Name	J. Brusca	Title: "HUMAN GENES AND GENE EXPRESSION PRODUCTS II"	
Attorney Docket	1481.002 <span style="float: right;">TECH CE: 90/290</span>																
First Named Inventor	Williams, et al.																
Application Number	09/297,648																
Filing Date	March 10, 2000																
Group Art Unit	1631																
Examiner Name	J. Brusca																
Title: "HUMAN GENES AND GENE EXPRESSION PRODUCTS II"																	
<b>ENCLOSURES (check all that apply)</b>																	
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%; vertical-align: top; padding: 5px;"> <input checked="" type="checkbox"/> Fee Transmittal Form   <input type="checkbox"/> Amendment/Response                <input type="checkbox"/> After Final                <input type="checkbox"/> Affidavits/declaration(s)   <input checked="" type="checkbox"/> Extension of Time Request   <input type="checkbox"/> Express Abandonment Request   <input type="checkbox"/> Information Disclosure Statement, 1449 and                <input type="checkbox"/> references   <input type="checkbox"/> Certified Copy of Priority Document(s)   <input type="checkbox"/> Response to Missing Parts/Incomplete Application   <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 (<i>with copy of Notice to File Missing Parts</i>)         </td> <td style="width: 33%; vertical-align: top; padding: 5px;"> <input type="checkbox"/> Issue Fee Transmittal (<i>with copy of PTOL-85B</i>)   <input type="checkbox"/> Formal Drawing(s)   <input type="checkbox"/> Licensing-related Papers   <input type="checkbox"/> Petition Routing Slip and Accompanying Petition   <input type="checkbox"/> To Convert a Provisional Application   <input type="checkbox"/> Power of Attorney                <input type="checkbox"/> Revocation                <input type="checkbox"/> Associate   <input type="checkbox"/> Change of Correspondence Address   <input type="checkbox"/> Terminal Disclaimer   <input type="checkbox"/> Small Entity Statement         </td> <td style="width: 33%; vertical-align: top; padding: 5px;"> <input type="checkbox"/> Request for Refund   <input type="checkbox"/> After Allowance Communication to Group   <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences   <input type="checkbox"/> Appeal Communication to Group (<i>Appeal Notice, Brief, Reply Brief</i>)   <input type="checkbox"/> Proprietary Information   <input type="checkbox"/> Status Letter   <input checked="" type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>):            1) Preliminary Amendment, Response to Restriction Requirement and Notice to Comply (w/copy of Notice to Comply)            2) Sequence Listing (hard copy and diskette)            3) Statement Regarding Sequence Listing            4) Return Postcard         </td> </tr> </table>				<input checked="" type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input checked="" type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement, 1449 and <input type="checkbox"/> references  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 ( <i>with copy of Notice to File Missing Parts</i> )	<input type="checkbox"/> Issue Fee Transmittal ( <i>with copy of PTOL-85B</i> )  <input type="checkbox"/> Formal Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition Routing Slip and Accompanying Petition  <input type="checkbox"/> To Convert a Provisional Application  <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Revocation <input type="checkbox"/> Associate  <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Request for Refund  <input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group ( <i>Appeal Notice, Brief, Reply Brief</i> )  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Additional Enclosure(s) ( <i>please identify below</i> ): 1) Preliminary Amendment, Response to Restriction Requirement and Notice to Comply (w/copy of Notice to Comply) 2) Sequence Listing (hard copy and diskette) 3) Statement Regarding Sequence Listing 4) Return Postcard											
<input checked="" type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input checked="" type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement, 1449 and <input type="checkbox"/> references  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 ( <i>with copy of Notice to File Missing Parts</i> )	<input type="checkbox"/> Issue Fee Transmittal ( <i>with copy of PTOL-85B</i> )  <input type="checkbox"/> Formal Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition Routing Slip and Accompanying Petition  <input type="checkbox"/> To Convert a Provisional Application  <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Revocation <input type="checkbox"/> Associate  <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Request for Refund  <input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group ( <i>Appeal Notice, Brief, Reply Brief</i> )  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Additional Enclosure(s) ( <i>please identify below</i> ): 1) Preliminary Amendment, Response to Restriction Requirement and Notice to Comply (w/copy of Notice to Comply) 2) Sequence Listing (hard copy and diskette) 3) Statement Regarding Sequence Listing 4) Return Postcard															
<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>																	
Individual Name	Karl Bozicevic		Registration No.	28,807													
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP																
Signature																	
Date	August 28, 2000																

# FEE TRANSMITTAL

Note: Effective October 1, 1998.  
Patent fees are subject to annual revision.

AUG 30 2000

U.S. PATENT & TRADEMARK OFFICE

Attorney Docket Number	2300-1481	RECEIVED
First Named Inventor	Williams, et al.	
Application Number	09/297,648	SEP - 5 2000
Filing Date	March 10, 2000	
Group Art Unit	1631	TECH CENTER 1600/2900
Examiner Name	J. Brusca	

## METHOD OF PAYMENT

- Check Is Enclosed
- ☒ The Commissioner is hereby authorized to charge the following and any additional fees including fees required under 37 CFR 1.16 and 1.17 and credit any overpayments to: Deposit Account No. 50-0815.  
Deposit Account Name: Bozicevic, Field & Francis LLP

## FEE CALCULATION

### 1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Due
101	690	201	345	Utility filing fee	\$
102	310	206	155	Design filing fee	
104	480	207	240	Plant filing fee	
109	690	208	345	Reissue filing fee	
110	150	214	75	Provisional filing fee	
Subtotal (1)					\$

### 2. CLAIMS

No. of claims as filed or after amendment		Most claims previously paid		Extra claims		Fee from below		Fee Due
Total claims	89	-	21	=	68	x	18	= \$1,224
Ind. claims	20	-	04	=	16	x	78	= \$1,248
Multiple Dependent claims						x		=

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	78	202	39	Independent claims in excess of 3
104	260	204	130	Multiple dependent claim
109	78	209	39	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of and over original patent

Subtotal (2) \$2,472.00


### 3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Due
105	130	205	65	Surcharge - late filing fee or oath	
139	130	139	130	Non-English specification	
115	110	215	55	Ext. for reply within first month	110
117	870	217	435	Ext. for reply within third month	
128	1,850	228	925	Ext. for reply within fifth month	
120	300	220	150	Filing brief in support of appeal	
140	110	240	55	Petition to revive - unavoidable	
142	1,210	242	605	Utility issue fee (or reissue)	
123	50	123	50	Petitions related to prov. appl.	
146	690	246	345	Filing submission after final rejection (37 CFR 1.129(a))	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
143	430	243	215	Design issue fee	
581	40	581	40	Recording patent assignment	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
147	2,520	147	2,520	Filing a request for reexamination	
116	380	216	190	Ext. for reply within second month	
118	1,360	218	680	Ext. for reply within fourth month	
119	300	219	150	Notice of Appeal	
121	260	221	130	Request for oral hearing	
141	1,210	241	605	Petition to revive - unintentional	
122	130	122	130	Petitions to the Commissioner	
126	240	126	240	Submission of IDS	
149	690	249	345	For each additional invention to be examined (37 CFR 1.129(b))	
113	1840*	113	1840*	Requesting publication of SIR after Examiner action	
144	580	244	290	Plant issue fee	
Other fee (specify)					

\* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) \$110.00

TOTAL AMOUNT TO BE CHARGED (\$2,582.00)

SUBMITTED BY				Complete (if applicable)	
Typed or Printed Name	Karl Bozicevic BOZICEVIC, FIELD & FRANCIS LLP			Reg. Number	28,807
Signature				Deposit Account	50-0815
	Date	Aug 28, 2000			

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**